Zika Virus: Information For Providers
Indications for Zika Virus Testing
The Indiana State Department of Health (ISDH) will assist in coordinating Zika virus testing based on the following CDC guidelines:
- Individuals with any of the FRAC (fever, rash, arthralgia, conjunctivitis) symptoms up to 12 weeks after symptom onset with travel to an area with Zika or who had unprotected sex with someone who has traveled to an area with Zika
- Pregnant women with any of the FRAC symptoms up to 12 weeks after symptom onset who have traveled to an area with Zika or had unprotected sex with someone who traveled to an area with Zika
- Any pregnant woman with recent possible Zika virus exposure who have ultrasonographic evidence of fetal abnormalities consistent with congenital Zika syndrome
If your patient meets these testing criteria, please complete the ISDH Zika Virus Authorization Form and follow the protocol below.
The CDC no longer recommends routine testing for:
- Asymptomatic pregnant women with apparently healthy babies who do not have ongoing Zika virus exposure
- These patients will no longer be eligible for testing at the ISDH Laboratories.
- If you believe an asymptomatic pregnant woman with an apparently healthy baby should be tested for Zika virus, then you may consider commercial testing. You are encouraged to consider factors such as type and duration of travel, the patient's use of prevention measures, timing of pregnancy, and current epidemiology of Zika virus transmission when making this decision.
These testing recommendations are based on the CDC Updated Interim Guidance, published July 2017.
Zika Virus Authorization Protocol for Providers
- Ensure symptomatic patient meets testing criteria using the ISDH Indications for Zika Virus Testing above.
- If patient meets criteria, complete the ISDH Zika Virus Authorization Form. Ensure all fields are completed and easily legible. Incomplete forms will result in a delay in authorization. Please ensure the “point of contact email address” provided is correct.
- Fax the completed ISDH Zika Virus Authorization Form to the ISDH Epidemiology Resource Center at 317-234-2812 to the attention of Emily Potts, Zika Virus Clinical Coordinator.
- If the specimen meets testing criteria, the point of contact will receive an approval email within one business day of submission. This email will include instructions and guidelines for specimen collection and submission to the ISDH Laboratories.
- Specimens received at the ISDH Laboratories with all appropriate paperwork will be tested and analyzed. The ISDH Laboratories offer two tests for Zika virus.
- Trioplex RT-PCR - This test can be performed on a blood or urine specimen to identify present virus.
- IgM Antibody (MAC-ELISA) - This test can be performed on a blood specimen to identify a recent past infection after virus is no longer present in blood or urine.
- Zika virus results may require 3 weeks turnaround time. In some cases, additional testing for Zika and dengue antibodies is needed via a complex virus neutralization test called PRNT (plaque reduction neutralization test). This test is done by the CDC and may take four to eight weeks.
- If a specimen does not meet testing criteria, the point of contact will receive an email from the Zika Virus Clinical Coordinator to discuss testing guidelines.
For questions regarding specimen authorization, please contact Taryn Stevens, Zoonotic and Vector-Borne Disease Epidemiologist, at 317-234-9727.
Zika Resources for Clinicians
Please view the updated Resource Guide for Clinicians below to identify resources to assist you with caring for pregnant women, women of reproductive age, and infants affected by Zika.
For more information for healthcare providers, please visit: https://www.cdc.gov/zika/hc-providers/index.html
For questions please contact Taryn Stevens, Vector-Borne Epidemiologist, at 317-234-9727.
Page last updated: April 26, 2018.
Page last reviewed: August 1, 2016